Mitochondrial-Derived Peptides: MOTS-c, Humanin and SS-31 Research Overview

Research Use Only. The compounds discussed here are supplied strictly as laboratory reagents. They are not medicines, not dietary supplements, and not intended for human or veterinary use. Nothing below is medical advice or a health claim.

Mitochondria were once treated as little more than the cell's power supply. Over the last two decades that picture has changed. Work on the mitochondrial genome has shown that it encodes a small family of short peptides that appear to act as signalling molecules rather than structural components, and this group has become one of the more active areas of preclinical laboratory investigation. This overview pulls together what the published literature reports about mitochondrial-derived peptides and the related mitochondria-targeted research compounds that sit alongside them.

What are mitochondrial-derived peptides?

Mitochondrial-derived peptides, usually abbreviated MDPs, are short peptides encoded by small open reading frames within mitochondrial DNA rather than by the nuclear genome. This was unexpected. The circular mitochondrial genome had long been described as encoding 37 genes covering transfer RNAs, ribosomal RNAs and a handful of proteins tied to the respiratory chain. The identification of additional coding sequences suggested the mitochondrial genetic repertoire is larger than the textbook description, and that mitochondria may send signals outward to the rest of the cell.

The three most frequently studied members are humanin, identified in the early 2000s, MOTS-c, described in 2015, and the SHLP family. In the published literature these peptides are often discussed as candidate retrograde signals, meaning molecules through which the mitochondrion communicates its metabolic status back to the nucleus and, in some models, to other tissues entirely.

Reported preclinical areas of investigation

• Glucose handling and insulin signalling in rodent models, particularly in skeletal muscle tissue
• Metabolic responses to exercise stress in animal models, with MOTS-c described as an exercise-sensitive peptide
• Cellular stress responses and cytoprotection in cultured cell systems
• Cellular senescence and the senescence-associated secretory phenotype, where results have been mixed and sometimes contradictory
• AMPK pathway activation and folate-methionine cycle interactions in vitro
• Correlative work relating circulating peptide concentrations to age in observational datasets

It is worth stating plainly that these are laboratory findings in cells and animals. They describe what has been measured under controlled experimental conditions, not outcomes in people.

Where these compounds sit in the research literature

MOTS-c

MOTS-c, short for mitochondrial open reading frame of the twelve S rRNA type-c, is a 16 amino acid peptide. Lee, Kim and Cohen described it as targeting skeletal muscle and influencing glucose metabolism in preclinical models, and framed it as an example of an active mitochondrial-encoded signal operating at both the cellular and organismal level. Later work by Woodhead and Merry examined MOTS-c in the context of exercise, reporting that acute high intensity exercise can raise measurable concentrations of MOTS-c and humanin in skeletal muscle and plasma. Those authors were careful to note that findings on chronic training effects are conflicting and depend heavily on the training protocol and the characteristics of the participants studied.

Humanin

Humanin was the first MDP identified and is a 24 amino acid peptide. Published reviews describe cytoprotective activity in cultured cells under various stressors, and correlative observations linking plasma concentrations to other endocrine markers. As with MOTS-c, the literature includes findings that complicate the simple narrative. Mendelsohn and Larrick reported that both humanin and MOTS-c can exacerbate the senescence-associated secretory phenotype in senescent cells by stimulating cytokine secretion, which sits somewhat awkwardly against the framing of MDPs as straightforwardly protective. Divergent results of this kind are normal in an emerging field and are a reason to treat any single study with caution.

SS-31 and mitochondria-targeted compounds

SS-31, also known as elamipretide, is not a mitochondrial-derived peptide. It is a synthetic tetrapeptide designed to associate with cardiolipin in the inner mitochondrial membrane, and it is grouped here because it shares the same research target rather than the same origin. Related compounds studied for mitochondrial function include NAD+ precursors, methylene blue and various redox-active molecules. Grouping them together is a convenience of subject matter, not a statement that they behave alike.

Chemistry and notes at a glance

• MOTS-c: 16 amino acid peptide, encoded within the mitochondrial 12S rRNA region, typically supplied as a lyophilized powder
• Humanin: 24 amino acid peptide, encoded within the mitochondrial 16S rRNA region, several analogues exist in the literature
• SS-31 (elamipretide): synthetic aromatic-cationic tetrapeptide, nuclear-encoded in origin, associates with cardiolipin
• Genomic origin: the defining feature of true MDPs is mitochondrial rather than nuclear encoding
• Analytical identity: confirm sequence identity by mass spectrometry and purity by HPLC before any experimental work

Why the research use only label matters

None of the compounds discussed here is an approved medicine in the European Union or elsewhere. MOTS-c and humanin are research peptides with no marketing authorisation of any kind. SS-31 has been the subject of clinical investigation by its developer, but investigational status is not approval, and material supplied as a research reagent is not the same thing as an investigational medicinal product prepared for a trial.

Under EU law, a material becomes a medicinal product largely through how it is presented. A chemical reagent sold with a therapeutic claim or with instructions implying human use falls under Directive 2001/83/EC as an unauthorised medicine, regardless of what the label says. This is why Pure Chems describes only published preclinical findings, in the third person, and never provides use instructions, protocols or dosing information of any kind. The framing is not a formality. It reflects the actual legal status of the material.

A note on anti-doping status is also warranted. Peptides in this space are frequently covered by the World Anti-Doping Agency Prohibited List under the broad categories for peptide hormones, growth factors and metabolic modulators, and category definitions are revised annually. Anyone whose work touches sport or competition should consult the current WADA list directly rather than relying on secondary summaries.

Handling and storage for researchers

The following describes standard laboratory practice for lyophilized peptide reagents. It is a description of bench technique, not a use instruction.

• Store sealed lyophilized vials at minus 20 degrees Celsius, protected from light. Short periods at 2 to 8 degrees Celsius during transit are generally tolerated for lyophilized material.
• Allow vials to reach ambient temperature before opening. Opening a cold vial draws in moist air and lyophilized peptides are hygroscopic.
• Reconstitute with an appropriate solvent for the peptide in question. Choice of solvent affects stability and is compound-specific. See our comparison of bacteriostatic water and acetic acid for reconstitution.
• Aliquot reconstituted solution into single-use volumes. Repeated freeze-thaw cycling is one of the most common causes of degradation and of irreproducible results between experimental runs.
• Record lot numbers and reconstitution dates. Cross-check the supplied certificate of analysis against your own expectations, as covered in our guide to peptide purity and the COA.

Frequently asked questions

What makes a peptide mitochondrial-derived?

The peptide must be encoded by an open reading frame within mitochondrial DNA rather than in the nuclear genome. Humanin and MOTS-c meet this definition. Compounds such as SS-31 target mitochondria but are synthetic and nuclear in origin, so they are mitochondria-targeted rather than mitochondrial-derived.

Are MOTS-c or humanin approved medicines anywhere?

No. Neither has marketing authorisation from the European Medicines Agency, the US Food and Drug Administration or any comparable regulator. Both exist solely as subjects of laboratory investigation, and material supplied by Pure Chems is a research reagent only.

Is MOTS-c legal to buy for research in the EU?

Research peptides of this type are generally handled in the EU as laboratory chemicals under the REACH framework rather than as medicinal products, and supplying them for documented research use is legal on that basis. That position depends entirely on the material being sold, described and used as a reagent. Member states apply their own additional rules, so institutions should verify national requirements before ordering.

Why do studies on these peptides sometimes disagree?

Because the field is young and the experimental systems vary widely. Cell type, animal strain, peptide concentration, exposure duration and the assay used all influence what gets measured. The senescence literature is a good example, with cytoprotective findings in some systems and pro-inflammatory signalling in others. Reading across several studies rather than relying on one is the sensible approach.

How should reconstituted peptide solutions be stored?

Aliquoted at minus 20 degrees Celsius or lower, protected from light, and thawed once. Reconstituted peptides are considerably less stable than lyophilized powder, so most laboratories reconstitute only what a given experiment requires.

Key takeaways

• Mitochondrial-derived peptides are short peptides encoded within mitochondrial DNA, with humanin and MOTS-c the best characterised examples.
• Published work describes them as candidate signalling molecules studied in the context of metabolism, exercise stress and cellular stress responses, entirely in cell and animal models.
• Findings are not uniform. Some reports complicate the cytoprotective framing, which is a normal feature of an emerging research area.
• SS-31 targets mitochondria but is synthetic and nuclear in origin, so it belongs to a different category despite the shared subject matter.
• None of these compounds is an approved medicine. All material is supplied for research use only.

Explore related research material

Pure Chems supplies MOTS-c for laboratory research with accompanying analytical documentation. For compound-specific detail, see our individual overviews of MOTS-c, humanin, SS-31 (elamipretide) and NAD+.

References

References sourced via PubMed.

1. Lee C, Kim KH, Cohen P. MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism. Free Radical Biology and Medicine, 2016;100:182-187. DOI | PubMed
2. Woodhead JST, Merry TL. Mitochondrial-derived peptides and exercise. Biochimica et Biophysica Acta (BBA) General Subjects, 2021;1865(12):130011. DOI | PubMed
3. Mendelsohn AR, Larrick JW. Mitochondrial-Derived Peptides Exacerbate Senescence. Rejuvenation Research, 2018;21(4):369-373. DOI | PubMed

Research Use Only. All products supplied by Pure Chems are laboratory reagents intended solely for in vitro research and laboratory experimentation by qualified professionals. They are not medicines and are not for human or veterinary use, consumption or administration. No statement on this page is a therapeutic or health claim.